Cargando…

Estimation and external validation of a new prognostic model for predicting recurrence-free survival for early breast cancer patients in the UK

BACKGROUND: We aimed to estimate and externally validate a new UK-specific prognostic model for predicting the long-term risk of a first recurrent event (local recurrence, metastatic recurrence, or second primary breast cancer) in women diagnosed with early breast cancer. METHODS: Using data on the...

Descripción completa

Detalles Bibliográficos
Autores principales: Campbell, H E, Gray, A M, Harris, A L, Briggs, A H, Taylor, M A
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2966633/
https://www.ncbi.nlm.nih.gov/pubmed/20823886
http://dx.doi.org/10.1038/sj.bjc.6605863
_version_ 1782189608461664256
author Campbell, H E
Gray, A M
Harris, A L
Briggs, A H
Taylor, M A
author_facet Campbell, H E
Gray, A M
Harris, A L
Briggs, A H
Taylor, M A
author_sort Campbell, H E
collection PubMed
description BACKGROUND: We aimed to estimate and externally validate a new UK-specific prognostic model for predicting the long-term risk of a first recurrent event (local recurrence, metastatic recurrence, or second primary breast cancer) in women diagnosed with early breast cancer. METHODS: Using data on the prognostic characteristics and outcomes of 1844 women treated for early breast cancer at the Churchill Hospital in Oxford, parametric regression-based survival analysis was used to estimate a prognostic model for recurrence-free survival. The model, which incorporated established prognostic factors, was externally validated using independent data. Its performance was compared with that of the Nottingham Prognostic Index (NPI) and Adjuvant! Online. RESULTS: The number of positive axillary lymph nodes, tumour grade, tumour size and patient age were strong predictors of recurrence. Oestrogen receptor (ER) positivity was shown to afford a moderate protective effect. The model was able to separate patients into distinct prognostic groups, and predicted well at the patient level, mean Brier Accuracy Score=0.17 (s.e.=0.004) and overall C=0.745 (95% CI, 0.717–0.773). Its performance diminished only slightly when applied to a second independent data set. When compared with the NPI, the model was able to better discriminate between women with excellent and good prognoses, and it did not overestimate 10-year recurrence-free survival to the extent observed for Adjuvant! Online. CONCLUSION: The model estimated here predicts well at both the individual patient and group levels, and appears transportable to patients treated at other UK hospitals. Its parametric form permits long-term extrapolation giving it an advantage over other prognostic tools currently in use. A simple point scoring system and reference table allow 5-, 10-, and 15-year predictions from the model to be quickly and easily estimated. The model is also available to download as an interactive computer program.
format Text
id pubmed-2966633
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-29666332011-09-07 Estimation and external validation of a new prognostic model for predicting recurrence-free survival for early breast cancer patients in the UK Campbell, H E Gray, A M Harris, A L Briggs, A H Taylor, M A Br J Cancer Clinical Study BACKGROUND: We aimed to estimate and externally validate a new UK-specific prognostic model for predicting the long-term risk of a first recurrent event (local recurrence, metastatic recurrence, or second primary breast cancer) in women diagnosed with early breast cancer. METHODS: Using data on the prognostic characteristics and outcomes of 1844 women treated for early breast cancer at the Churchill Hospital in Oxford, parametric regression-based survival analysis was used to estimate a prognostic model for recurrence-free survival. The model, which incorporated established prognostic factors, was externally validated using independent data. Its performance was compared with that of the Nottingham Prognostic Index (NPI) and Adjuvant! Online. RESULTS: The number of positive axillary lymph nodes, tumour grade, tumour size and patient age were strong predictors of recurrence. Oestrogen receptor (ER) positivity was shown to afford a moderate protective effect. The model was able to separate patients into distinct prognostic groups, and predicted well at the patient level, mean Brier Accuracy Score=0.17 (s.e.=0.004) and overall C=0.745 (95% CI, 0.717–0.773). Its performance diminished only slightly when applied to a second independent data set. When compared with the NPI, the model was able to better discriminate between women with excellent and good prognoses, and it did not overestimate 10-year recurrence-free survival to the extent observed for Adjuvant! Online. CONCLUSION: The model estimated here predicts well at both the individual patient and group levels, and appears transportable to patients treated at other UK hospitals. Its parametric form permits long-term extrapolation giving it an advantage over other prognostic tools currently in use. A simple point scoring system and reference table allow 5-, 10-, and 15-year predictions from the model to be quickly and easily estimated. The model is also available to download as an interactive computer program. Nature Publishing Group 2010-09-07 2010-09-07 /pmc/articles/PMC2966633/ /pubmed/20823886 http://dx.doi.org/10.1038/sj.bjc.6605863 Text en Copyright © 2010 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Clinical Study
Campbell, H E
Gray, A M
Harris, A L
Briggs, A H
Taylor, M A
Estimation and external validation of a new prognostic model for predicting recurrence-free survival for early breast cancer patients in the UK
title Estimation and external validation of a new prognostic model for predicting recurrence-free survival for early breast cancer patients in the UK
title_full Estimation and external validation of a new prognostic model for predicting recurrence-free survival for early breast cancer patients in the UK
title_fullStr Estimation and external validation of a new prognostic model for predicting recurrence-free survival for early breast cancer patients in the UK
title_full_unstemmed Estimation and external validation of a new prognostic model for predicting recurrence-free survival for early breast cancer patients in the UK
title_short Estimation and external validation of a new prognostic model for predicting recurrence-free survival for early breast cancer patients in the UK
title_sort estimation and external validation of a new prognostic model for predicting recurrence-free survival for early breast cancer patients in the uk
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2966633/
https://www.ncbi.nlm.nih.gov/pubmed/20823886
http://dx.doi.org/10.1038/sj.bjc.6605863
work_keys_str_mv AT campbellhe estimationandexternalvalidationofanewprognosticmodelforpredictingrecurrencefreesurvivalforearlybreastcancerpatientsintheuk
AT grayam estimationandexternalvalidationofanewprognosticmodelforpredictingrecurrencefreesurvivalforearlybreastcancerpatientsintheuk
AT harrisal estimationandexternalvalidationofanewprognosticmodelforpredictingrecurrencefreesurvivalforearlybreastcancerpatientsintheuk
AT briggsah estimationandexternalvalidationofanewprognosticmodelforpredictingrecurrencefreesurvivalforearlybreastcancerpatientsintheuk
AT taylorma estimationandexternalvalidationofanewprognosticmodelforpredictingrecurrencefreesurvivalforearlybreastcancerpatientsintheuk